经腋窝途径微创孤立性主动脉瓣置换术:1000例连续患者结果
本研究报道了1000例连续接受经腋窝微创主动脉瓣置换术患者的临床结果。2019至2023年间,经腋窝途径使用率从18.7%升至97.8%,平均手术时间127分钟,交叉钳夹时间43分钟,转换率1.9%,30天主要不良心脑血管事件1.9%,死亡率0.9%。结论认为该技术安全有效且美容效果好,在选定患者中微创率可超过95%。
要点
- 经腋窝微创主动脉瓣置换术30天死亡率0.9%,主要不良心脑血管事件1.9%。
- 术中使用快速部署瓣膜占81.1%,缝合生物瓣占14.5%,缝合机械瓣占4.1%。
- 术中转换、输血和呼吸衰竭是主要不良心脑血管事件的独立危险因素。
核心结论
- 经腋窝微创主动脉瓣置换术是安全、有效且美容效果满意的外科主动脉瓣置换方法。
- 在选定患者中,该技术有潜力使微创心脏手术率超过95.0%。
研究设计与样本
- 回顾性单中心研究,纳入2019至2023年间首批连续1000例经腋窝孤立性微创主动脉瓣置换术患者。
- 排除感染性心内膜炎、再次手术或联合手术者;平均年龄67.9±8.3岁,STS-PROM 1.39±2.89%,EuroScore II 1.65±1.12%。
主要发现
- 经腋窝途径使用率从2019年的18.7%增加至2023年的97.8%。
- 平均手术时间127±31分钟,平均交叉钳夹时间43±14分钟,转换率1.9%。
- 30天主要不良心脑血管事件发生率1.9%,包括死亡率0.9%、围术期卒中0.8%和心肌梗死0.6%。
- 主要不良心脑血管事件的多因素分析:术中转换OR 1.08(1.00-1.16),P=0.04;术中输血OR 1.21(1.07-1.38),P<0.01;呼吸衰竭OR 1.39(1.30-1.49),P<0.01。
- 死亡的多因素分析:胰岛素治疗糖尿病OR 1.02(1.00-1.04),P=0.03;纯主动脉瓣反流为主要指征OR 1.03(1.01-1.05),P<0.01;术中转换OR 1.11(1.07-1.16),P<0.01;肾衰竭OR 1.08(1.05-1.10),P<0.01;呼吸衰竭OR 1.22(1.17-1.26),P<0.01。
临床怎么用
- 经腋窝途径可作为选定患者外科主动脉瓣置换的微创选择,美容效果好且围术期风险可接受。
- 术前应评估胰岛素依赖糖尿病、纯主动脉瓣反流、肾功能等死亡危险因素,并尽量优化以减少术中转换、输血和呼吸衰竭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The transaxillary concept for minimally invasive cardiac surgery-aortic valve replacement is a new and versatile approach with nearly no visible scars. Due to its novelty, available data in literature are scarce. This study reports clinical outcomes of 1000 consecutive patients. METHODS: Between 2019 and 2023, 4394 patients underwent elective isolated aortic valve procedures, with 2958 (67.5%) transcatheter aortic valve implantation's and 1436 patients surgical aortic valve replacement's (32.5%). Within this period, 1st consecutive 1000 transaxillary isolated minimally invasive cardiac surgery-aortic valve replacement were enrolled. Endocarditis, redo's or combined procedures were excluded. Mean age was 67.9 ± 8.3 years, STS-PROM 1.39 ± 2.89% and EuroScore II 1.65 ± 1.12%. RESULTS: Use of the transaxillary access increased from 18.7% (2019) to 97.8% (2023). Mean procedure time was 127 ± 31 min, and average cross-clamp time was 43 ± 14 min. Used prostheses were rapid deployment (81.1%), sutured biologic (14.5%) or sutured mechanical valves (4.1%). Conversion rate was 1.9%. No patient died intraoperatively. Thirty-day major adverse cardiac and cerebrovascular event was 1.9% including 0.9% mortality, 0.8% perioperative stroke and 0.6% myocardial infarction. Multivariate factors for major adverse cardiac and cerebrovascular event are intraoperative conversion [OR 1.08 (1.00-1.16); P = 0.04], intraoperative transfusions [OR 1.21 (1.07-1.38); P < 0.01] and respiratory failure [OR 1.39 (1.30-1.49); P < 0.01]. Corresponding factors for mortality are diabetes on insulin [OR 1.02 (1.00-1.04); P = 0.03], pure aortic regurgitation for primary indication [OR 1.03 (1.01-1.05); P < 0.01], intraoperative conversion [OR 1.11 (1.07-1.16); P < 0.01], renal failure [OR 1.08 (1.05-1.10); P < 0.01] and respiratory failure [OR 1.22 (1.17-1.26); P < 0.01]. CONCLUSIONS: Transaxillary minimally invasive cardiac surgery-aortic valve replacement is a safe, effective and cosmetically convincing method for surgical aortic valve replacement, having the potential for >95.0% minimally invasive cardiac surgery rate in selected patients.
引用
- Wilbring M, Arzt S, Taghizadeh-Waghefi A, et al. The transaxillary concept for minimally invasive isolated aortic valve replacement: results of 1000 consecutive patients. Eur J Cardiothorac Surg. 2024. PMID: 39602603. doi:10.1093/ejcts/ezae427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。